Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor

Therapeutic Drug Monitoring

Volumn 30, Issue 1, 2008, Pages 113-116

  Brandhorst, Gunnar ^a   Tenderich, Gero ^b   Zittermann, Armin ^b   Oezpeker, Cenk ^b   Koerfer, Reiner ^b   Oellerich, Michael ^a   Armstrong, Victor William ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cyclosporine; Everolimus; Interaction; Therapeutic drug monitoring; Transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; CYTOCHROME P450 3A4; EVEROLIMUS; GLYCOPROTEIN P; TACROLIMUS;

ADULT; AGED; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG MONITORING; FEMALE; HEART GRAFT; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

AREA UNDER CURVE; AZATHIOPRINE; CALCINEURIN; CYCLOSPORINE; DRUG ANTAGONISM; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS;

EID: 38549132528     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318161a335     Document Type: Article

References (13)

1. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments. Ther Drug Monit. 2006;28:720-725.
2. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation. 2000;70:690-694.
3. McAlister VC, Gao ZH, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet. 2000;355:376-377.
4. Zimmerman JJ, Harper D, Getsy J, et al. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol. 2003;43:1168-1176.
5. Podder H, Stepkowski SM, Napoli K, et al. Pharmacokinetic interactions between sirolimus and cyclosporine exacerbate renal dysfunction. Transplant Proc. 2001;33:1086.
6. Podder H, Podbielski J, Hussein I, et al. Impact of sirolimus on renal transplant outcomes in African Americans. Transplant Proc. 2001;33:1226.
7. Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002;42:95-99.
8. Kovarik JM, Dantal J, Civati G, et al. Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. Am J Transplant. 2003;3:1576-1580.
9. Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc. 2006;38:3456-3458.
10. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem. 2002;48:955-958.
11. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499-505.
12. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos. 2006;27:421-426.
13. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2006;28:39-44.